The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials


Aims
The effect of statins on risk of heart failure (HF) hospitalization and HF death remains uncertain. We aimed to establish whether statins reduce major HF events.

Methods
We searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized controlled endpoint statin trials from 1994 to 2014. Collaborating trialists provided unpublished data from adverse event reports. We included primary- and secondary-prevention statin trials with >1000 participants followed for >1 year. Outcomes consisted of first non-fatal HF hospitalization, HF death and a composite of first non-fatal HF hospitalization or HF death. HF events occurring <30 days after within-trial myocardial infarction (MI) were excluded. We calculated risk ratios (RR) with fixed-effects meta-analyses. In up to 17 trials with 132 538 participants conducted over 4.3 years, statin therapy reduced LDL-cholesterol by 0.97 mmol/L (weighted SD 0.38 mmol/L). Statins reduced the numbers of patients experiencing non-fatal HF hospitalization (1344/66 238 vs. 1498/66 330; RR 0.90, 95% confidence interval, CI 0.84–0.97) and the composite HF outcome (1234/57 734 vs. 1344/57 836; RR 0.92, 95% CI 0.85–0.99) but not HF death (213/57 734 vs. 220/57 836; RR 0.97, 95% CI 0.80–1.17). The effect of statins on first non-fatal HF hospitalization was similar whether this was preceded by MI (RR 0.87, 95% CI 0.68–1.11) or not (RR 0.91, 95% CI 0.84–0.98).

Conclusion
In primary- and secondary-prevention trials, statins modestly reduced the risks of non-fatal HF hospitalization and a composite of non-fatal HF hospitalization and HF death with no demonstrable difference in risk reduction between those who suffered an MI or not.

Keywords
Statin • Heart failure • Randomized trial • Prevention • Meta-analysis

*Corresponding author. Tel. +44 141 3303076, Fax. +44 141 3306955, Email: david.preiss@glasgow.ac.uk
© The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Heart failure (HF) is a condition characterized by debilitating symptoms, a particularly poor quality of life, frequent hospital admissions and reduced survival. It also places a major economic burden on healthcare systems. Consequently, therapies which reduce the risk of developing HF are highly desirable and likely to be cost effective. Coronary heart disease is reported to be the most common cause of HF. Statin therapy has been conclusively shown to reduce the risk of myocardial infarction (MI) in primary- and secondary-prevention populations. By reducing first and recurrent injurious myocardial events, statin therapy should reduce the development of HF. It is also possible that statin therapy may influence the development of HF by other mechanisms.

To date, about half of the major placebo- and standard care-controlled statin endpoint trials have published data on a variety of HF outcomes and a borderline reduction in HF hospitalization or HF death was only shown in one trial. Data regarding HF hospitalization from four dose-comparison trials have been pooled with the overall result suggesting that intensive statin therapy reduces HF hospitalization compared with moderate dose therapy. However, the types of HF endpoints have varied somewhat with some trials reporting any HF adverse event, some reporting HF death, some reporting non-fatal HF hospitalization, and some reporting a composite of fatal and non-fatal HF events. This heterogeneity in the categories of HF outcomes collected, along with missing information, has precluded a comprehensive pooling of HF data. In addition, none of the existing reports described whether any effect on HF hospitalization might be fully explained by preventing precursor MIs.

The purpose of this analysis was to obtain comprehensive and harmonized data for major HF events (non-fatal hospitalization, death, and a composite of both) in major statin trials for the purpose of evaluating whether, and if so to what extent, statin therapy may reduce major HF events. In addition, we wished to explore whether any reduction in HF was primarily driven by a reduction in non-fatal MI.

Methods

Data sources and searches

We collected data from major randomized controlled trials designed to assess the effect of statins on cardiovascular outcomes. We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with the terms ‘statin’ and ‘HMG CoA reductase inhibitor’, plus individual statin names as title or keywords, on 25th March 2014.

Study selection

We limited the search to trials of adults, published in the English language, between 1 January 1994 and 1 January 2014. We included placebo-controlled, standard care-controlled, and intensive vs. moderate dose trials in primary prevention, secondary-prevention, and mixed primary- and secondary-prevention populations. We excluded trials conducted entirely in participants with HF, dialysis, or organ transplant populations, those with <1000 enrolled participants, trials with a mean follow-up of <1 year, trials of combination therapy, and trials assessing surrogate markers of cardiovascular disease. Study protocol and data request sheets were sent to investigators from the relevant trials as described below to collect unpublished data (Supplementary material online, Appendix). A specific definition of HF events was not provided to the contributing investigators.

Data extraction and quality assessment

Two researchers (R.C. and D.P.) independently reviewed abstracts and manuscripts to identify relevant trials. A third reader (J.J.M.) resolved any discrepancies. An assessment of study design and quality for each trial was made using the Jadad score. Our search strategy identified 23 potentially suitable trials for which unpublished data were sought (Figure 1). The study was conducted according to published Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Unpublished tabular data were collected regarding the numbers of participants who experienced a non-fatal hospitalization for HF, the number that died due to HF, and the number that suffered either a non-fatal HF hospitalization or HF death (composite HF outcome) in each arm. Investigators were asked to detail the number of participants with HF at randomization in both treatment arms (where available), LDL-cholesterol levels at randomization and 1 year, and the number of participants who suffered a within-trial non-fatal MI. Numbers with incident HF events were also requested separately in only those participants without HF at baseline. Heart failure events occurring <30 days after within-trial MI were specifically excluded from unpublished data sought from collaborating trials. This decision was driven by the following considerations: events within 30 days of MI would have been variably recorded as many participants would still have been in hospital due to the index MI (i.e. some events would still not be captured by assessing HF hospitalization); development of HF soon after MI may be transient, reflecting cardiac stunning, and may not necessarily lead to chronic HF; and if participants developed clinically significant HF they may well have suffered a subsequent HF hospitalization in the trial anyway. Of the 23 trials, 17 trials were able to provide unpublished HF data, with HF events occurring <30 days after within-trial MI excluded. These results were analysed for the main HF analyses. For the remaining six trials, HF outcomes were available from four trials (three with published data; one with unpublished data). Data regarding timing of incident cases of HF with regard to within-trial (i.e. post-randomization) MI were not available in these four trials with the result that HF events within 30 days of MI could not be excluded and their results were therefore only combined with the full dataset in sensitivity analyses. Two authors (D.P. and R.C.) independently abstracted and tabulated information about the number of participants without HF at baseline and incident cases of HF according to randomization group in those trials where only published data were available.

Data synthesis and analysis

To identify potential relationships of statins with the risk of developing HF, we calculated risk ratios (RRs) as the ratio of cumulative incidence and 95% confidence intervals (CIs) from the available data for all trial participants at baseline and for those who experienced an HF event during trial follow-up. Study-specific RRs were pooled using fixed-effects model meta-analysis. Statistical heterogeneity across studies was quantified using the I² statistic, with $I^2 > 0.10$ considered statistically non-significant. The I² statistic is derived from the Q statistic ($Q = df(Q) \times 100$) and provides a measure of the proportion of the overall variation attributable to between-study heterogeneity. We also separately analysed the risk of HF events depending on whether a participant had or had not suffered a preceding within-trial MI. However, the available data did not allow a formal statistical comparison of those who had and had not suffered a preceding within-trial MI.

Placebo- and standard care-controlled statin trials as well as dose-comparison statin trials were combined in all analyses though their respective pooled results were also compared by fixed-effect inverse-
Figure 1  Flow diagram of literature search to identify randomized placebo-controlled trials, standard care-controlled trials, and dose-comparison statin trials.
Trials were generally of high quality with a median Jadad score of 5 and a weighted mean of 0.97 mmol/L (weighted SD 0.38 mmol/L). Mortality (non-significant) in the mixed trials and 200 (95% CI 0.86–1.01) respectively.

Influence of statin therapy on risk of heart failure events preceded or not preceded by myocardial infarction

Only 10–15% of first composite HF outcomes as well as non-fatal HF hospitalizations were preceded by a documented within-trial non-fatal MI (this excludes all HF events within 30 days of MI). There was no demonstrable difference between the effect of statin therapy on risk of a first HF event preceded by a within-trial MI or not (Table 2). For non-fatal hospitalization, RRs were 0.87 (95% CI 0.68–1.11) and 0.91 (95% CI 0.84–0.98) while for the composite HF outcome RRs were 0.86 (95% CI 0.68–1.09) and 0.94 (95% CI 0.86–1.01), respectively.

Sensitivity analyses

There was no evidence of any difference in the effect of statin therapy on HF events in primary prevention, secondary prevention, and mixed trial populations (P = 0.42; Supplementary material online, Figure S3). Similarly, no difference was demonstrated between placebo/standard care-controlled trials and dose-comparison trials (P = 0.23; Supplementary material online, Figure S4). We tested whether there was any heterogeneity between trials which did or did not pre-specify any HF event as a secondary or tertiary outcome and, again, no difference was found (P = 0.62; Supplementary material online, Figure S5). When random effects meta-analysis was employed for non-fatal HF hospitalization, results were identical to those obtained from fixed-effect meta-analysis, namely RR 0.90 (95% CI 0.84–0.97).

The analyses were repeated with the inclusion of data from the four trials (additional 24 560 participants) which did not report timing of within-trial MI. Results were similar to the main analyses (Supplementary material online, Table S2).

Discussion

This study demonstrates that statin therapy led to reductions in the number of patients suffering HF events in major primary- and secondary-prevention trials over ~4 years of follow-up. The risks of both non-fatal hospitalization and the composite HF outcome (non-fatal HF hospitalization or HF death) were reduced by ~10%.
<table>
<thead>
<tr>
<th>Trial</th>
<th>Year</th>
<th>Trial population</th>
<th>Active arm (n)</th>
<th>Control arm (n)</th>
<th>Age (years)</th>
<th>LDL-c (mmol/L)</th>
<th>Follow-up (years)</th>
<th>Women (%)</th>
<th>Percentage with HF at baseline (%)</th>
<th>Was HF a pre-specified endpoint?</th>
<th>Included in main HF analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>4S</td>
<td>1994</td>
<td>Secondary</td>
<td>Simvastatin 10–40 mg (2221)</td>
<td>Placebo (2223)</td>
<td>58.5 (–)</td>
<td>4.87 (0.66)</td>
<td>5.4 (–)*</td>
<td>19</td>
<td>–</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>WOSCOPS</td>
<td>1995</td>
<td>Primary</td>
<td>Pravastatin 40 mg (3302)</td>
<td>Placebo (3293)</td>
<td>55.2 (5.5)</td>
<td>4.96 (0.45)</td>
<td>4.81 (0.78)</td>
<td>0</td>
<td>0.0</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>CARE</td>
<td>1996</td>
<td>Secondary</td>
<td>Pravastatin 40 mg (2081)</td>
<td>Placebo (2078)</td>
<td>58.6 (9.3)</td>
<td>3.59 (0.38)</td>
<td>4.83 (0.94)</td>
<td>14</td>
<td>7.2</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>AFCAPS Texans</td>
<td>1998</td>
<td>Primary</td>
<td>Lovastatin 20–40 mg (3304)</td>
<td>Placebo (3301)</td>
<td>58 (7)</td>
<td>3.89 (0.43)</td>
<td>5.2 (0.9)</td>
<td>15</td>
<td>0.0</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>LIPID</td>
<td>1998</td>
<td>Secondary</td>
<td>Pravastatin 40 mg (4512)</td>
<td>Placebo (4502)</td>
<td>62 (–)*</td>
<td>3.88 (3.36–4.40)*</td>
<td>6.1 (–)</td>
<td>17</td>
<td>–</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>GISSI PREVENZIONE</td>
<td>2000</td>
<td>Secondary</td>
<td>Pravastatin 20 mg (2138)</td>
<td>No treatment (2133)</td>
<td>59.9 (10.4)</td>
<td>3.92 (0.67)</td>
<td>1.9 (0.6)</td>
<td>14</td>
<td>16.1</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>HPS</td>
<td>2002</td>
<td>Mixed</td>
<td>Simvastatin 40 mg (10 269)</td>
<td>Placebo (10 267)</td>
<td>64 (8.4)</td>
<td>3.38 (0.83)</td>
<td>5 (1.1)</td>
<td>25</td>
<td>–</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>PROSPER</td>
<td>2002</td>
<td>Mixed</td>
<td>Pravastatin 40 mg (2891)</td>
<td>Placebo (2913)</td>
<td>75.3 (3.4)</td>
<td>3.79 (0.80)</td>
<td>3.2 (0.63)</td>
<td>52</td>
<td>–</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>GREACE</td>
<td>2002</td>
<td>Secondary</td>
<td>Atorvastatin 10–80 mg (800)</td>
<td>Usual care (800)</td>
<td>59 (12)</td>
<td>4.65 (0.62)</td>
<td>3 (1)</td>
<td>22</td>
<td>–</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ALLHAT-LLT</td>
<td>2002</td>
<td>Mixed</td>
<td>Pravastatin 40 mg (5170)</td>
<td>Usual care (5185)</td>
<td>66.6 (7.6)</td>
<td>3.76 (0.55)</td>
<td>4.8 (1.3)</td>
<td>49</td>
<td>0.0</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ASCOT-LLA</td>
<td>2003</td>
<td>Primary</td>
<td>Atorvastatin 10 mg (5134)</td>
<td>Placebo (5106)</td>
<td>62.7 (8.5)</td>
<td>3.44 (0.72)</td>
<td>3.2 (0.6)</td>
<td>19</td>
<td>0.0</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>CARDS</td>
<td>2004</td>
<td>Primary</td>
<td>Atorvastatin 10 mg (1428)</td>
<td>Placebo (1410)</td>
<td>61.6 (8.1)</td>
<td>3.03 (0.71)</td>
<td>3.84 (1.06)</td>
<td>32</td>
<td>0.1</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ALLIANCE</td>
<td>2004</td>
<td>Secondary</td>
<td>Atorvastatin 10–80 mg (1217)</td>
<td>Usual care (1225)</td>
<td>61.2 (8.8)</td>
<td>3.80 (0.68)</td>
<td>4.29 (1.5)</td>
<td>18</td>
<td>6.8</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>AT Z</td>
<td>2004</td>
<td>Secondary</td>
<td>Simvastatin 40–80 mg (2265)</td>
<td>Placebo + Simvastatin 20 mg (2332)</td>
<td>61 (53–69)*</td>
<td>2.87 (2.46–3.39)*</td>
<td>2.0 (–)*</td>
<td>24</td>
<td>–</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>TNT</td>
<td>2005</td>
<td>Secondary</td>
<td>Atorvastatin 80 mg (4995)</td>
<td>Atorvastatin 10 mg (5006)</td>
<td>61 (8.8)</td>
<td>2.52 (0.45)</td>
<td>4.9 (0.76)</td>
<td>19</td>
<td>7.8</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>IDEAL</td>
<td>2005</td>
<td>Secondary</td>
<td>Atorvastatin 80 mg (4439)</td>
<td>Simvastatin 20–40 mg (4449)</td>
<td>61.7 (9.5)</td>
<td>3.14 (0.90)</td>
<td>4.62 (0.82)</td>
<td>19</td>
<td>6.0</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ASPEN</td>
<td>2006</td>
<td>Mixed</td>
<td>Atorvastatin 10 mg (1211)</td>
<td>Placebo (1199)</td>
<td>61 (8.2)</td>
<td>2.93 (0.66)</td>
<td>4 (0.55)</td>
<td>34</td>
<td>0.4</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MEGA</td>
<td>2006</td>
<td>Primary</td>
<td>Pravastatin 10–20 mg (3866)</td>
<td>Usual care (3966)</td>
<td>58.3 (7.2)</td>
<td>4.05 (0.45)</td>
<td>5.29 (1.92)</td>
<td>68</td>
<td>0.1</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>SPARCL</td>
<td>2006</td>
<td>Primary</td>
<td>Atorvastatin 80 mg (2365)</td>
<td>Placebo (2366)</td>
<td>62.8 (11.3)</td>
<td>3.45 (0.62)</td>
<td>4.8 (1.1)</td>
<td>40</td>
<td>0.4</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>JUPITER</td>
<td>2008</td>
<td>Primary</td>
<td>Rosuvastatin 20 mg (8901)</td>
<td>Placebo (8901)</td>
<td>66.1 (7.7)</td>
<td>2.70 (0.48)</td>
<td>2.1 (0.9)</td>
<td>38</td>
<td>0.3</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>SEARCH</td>
<td>2010</td>
<td>Secondary</td>
<td>Simvastatin 80 mg (6031)</td>
<td>Simvastatin 20 mg (6033)</td>
<td>64.2 (8.9)</td>
<td>2.50 (0.61)</td>
<td>6.7 (1.5)</td>
<td>17</td>
<td>–</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

HF, heart failure; LDL-c, low-density lipoprotein cholesterol. Data are listed as mean (SD) or *median (interquartile range).
**Figure 2** The effect of statin therapy on the risk of (A) first non-fatal heart failure hospitalization in 17 trials (B) heart failure death in 14 trials (C) first composite heart failure outcome in 14 trials. All heart failure events within 30 days of myocardial infarction were excluded.
driven by a reduction in non-fatal hospitalization. This modest benefit appeared similar in those with and without a history of coronary heart disease at baseline, and across both placebo- and standard care-controlled trials, as well as dose-comparison trials. In contrast, no reduction in HF death was noted though there were fewer events and a small treatment benefit cannot be excluded. While relative risk reductions for HF hospitalizations on statins were similar in primary- and secondary-prevention trial participants, the absolute risk reduction was considerably greater in secondary-prevention participants whose HF event rates were substantially higher.

Pooled results for HF hospitalizations were previously available from four dose-comparison statin trials \((n = 27,546)\) in participants with established coronary heart disease, some of whom had HF at baseline. These results published in 2006, which included HF events within 30 days of MI, showed a 27% reduction in this endpoint. Of the previously published HF data from trials comparing statins to placebo or standard care, only the Heart Protection Study (HPS) demonstrated a reduction in any major HF event, namely a borderline significant reduction of 14% in the composite outcome of HF death and non-fatal HF hospitalization on simvastatin compared with placebo \([354 \text{ vs. } 405 \text{ first events, RR 0.86 (95% CI 0.75–1.00)}]\).\(^4\) In HPS, there were also trends towards reductions in both HF death and non-fatal hospitalizations, respectively.\(^4\,33\) However, other trials had found no such benefit, underlining the need for a comprehensive synthesis of trial data.

Notably, we found that the benefit of statin therapy for HF outcomes appeared similar regardless of whether an antecedent MI occurred or not. For example, the number of participants requiring hospitalization for non-fatal HF without a preceding within-trial MI was significantly reduced by statins, to a similar extent as that observed for participants with an earlier within-trial MI. A second notable finding was that the proportion of participants experiencing HF events was dominated by those without an earlier within-trial MI. Indeed, \(\sim 85–90\%\) of HF events were not preceded by a documented within-trial MI. There are various potential explanations for...
these two observations. With respect to the issue of preceding MI, both the requirement for potential events to fulfil adjudication requirements and the historical nature of the trials may have resulted in an underestimation of the numbers of within-trial MIs. Events that did not have complete documentation and the use of insensitive biomarkers may have led to this. It is also recognized that myocardial ischaemia, as well as MI, may result in reduced left ventricular systolic function and, in patients with pre-existing systolic dysfunction (which many participants in the present trials may have had), precipitate HF. For example, in the Studies of Left Ventricular Dysfunction trials, episodes of unstable angina led to a 60% increase in risk of subsequent HF hospitalization. Even myocardial ischaemia that is not acutely symptomatic, or symptomatic at all, may lead to left ventricular diastolic and systolic dysfunction (manifest in the most extreme cases as ‘hibernating myocardium’). Statins reduce symptomatic myocardial ischaemia and may also reduce asymptomatic episodes. An alternative and more controversial explanation is that statins may not only reduce the risk of developing HF by preventing ischaemic events but also by unrecognized pleiotropic mechanisms unlinked to LDL-cholesterol reduction, such as anti-inflammatory effects.

The HF benefit of statin therapy is likely to be underestimated in our analysis to some extent. Our analysis was limited to hospitalization and excluded milder episodes where hospitalization was not required. Importantly, the development of HF often leads to repeated hospital admissions but our analysis was limited to the required. Importantly, the development of HF often leads to exclusion and excluded milder episodes where hospitalization was not included. Our analysis was designed to investigate the effect of statin therapy on the development of HF and so could not address statins’ potential effect on repeat HF hospitalization in those with existing HF. However, the effect size we observed with statins was similar to that observed in the CORONA trial which compared rosuvastatin to placebo in patients with established systolic HF (5011 participants of whom 1291 were hospitalized (2408 events) for HF, HR 0.91, 95% CI 0.82–1.02). In CORONA, statin therapy significantly reduced both the risk of repeat HF admissions and the overall number of admissions.

Our analysis was designed to investigate the effect of statin therapy on the development of HF and so could not address statins’ potential effect on repeat HF hospitalization in those with existing HF. However, the effect size we observed with statins was similar to that observed in the CORONA trial which compared rosuvastatin to placebo in patients with established systolic HF (5011 participants of whom 1291 were hospitalized (2408 events) for HF, HR 0.91, 95% CI 0.82–1.02). In CORONA, statin therapy significantly reduced both the risk of repeat HF admissions and the overall number of admissions.

### Table 2 Effect of statin therapy on heart failure events according to the presence or absence of a previous within-trial myocardial infarction

<table>
<thead>
<tr>
<th>Event Type</th>
<th>Number of trials</th>
<th>First events/n on statin, first events/n on control therapy</th>
<th>Risk ratio (95% CI)</th>
<th>I² (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-fatal heart failure hospitalization</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First non-fatal hospitalization</td>
<td>17</td>
<td>1344/66 238, 1498/66 300</td>
<td>0.90 (0.84–0.97)</td>
<td>0</td>
</tr>
<tr>
<td>No MI preceding first non-fatal hospitalization</td>
<td>15</td>
<td>1096/63 357, 1211/63 452</td>
<td>0.91 (0.84–0.98)</td>
<td>0</td>
</tr>
<tr>
<td>MI preceding first non-fatal hospitalization</td>
<td>15</td>
<td>119/63 357, 137/63 452</td>
<td>0.87 (0.68–1.11)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Heart failure death</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>14</td>
<td>213/57 734, 220/57 836</td>
<td>0.97 (0.80–1.17)</td>
<td>0</td>
</tr>
<tr>
<td>No MI preceding death</td>
<td>13</td>
<td>178/56 934, 181/57 036</td>
<td>0.98 (0.80–1.21)</td>
<td>0</td>
</tr>
<tr>
<td>MI preceding death</td>
<td>7</td>
<td>33/33 124, 35/33 232</td>
<td>0.95 (0.59–1.51)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Heart failure composite outcome (death or non-fatal hospitalization)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First composite outcome</td>
<td>14</td>
<td>1234/57 734, 1344/57 836</td>
<td>0.92 (0.85–0.99)</td>
<td>0</td>
</tr>
<tr>
<td>No MI preceding first composite outcome</td>
<td>13</td>
<td>1093/56 934, 1170/57 036</td>
<td>0.94 (0.86–1.01)</td>
<td>0</td>
</tr>
<tr>
<td>MI preceding first composite outcome</td>
<td>12</td>
<td>128/48 033, 149/48 135</td>
<td>0.86 (0.68–1.09)</td>
<td>0</td>
</tr>
</tbody>
</table>

*All HF events occurring <30 days after within-trial MI excluded from analysis.*
to the nature of the data; however, limited heterogeneity for all the analyses provides some confidence that any such variation did not introduce systematic bias. Third, data were missing for some of the HF endpoints and not all major statin trials could be included. Fourth, we were unable to conduct a formal statistical comparison of the HF risks of participants who did and did not experience a within-trial MI prior to developing HF, but the large degree of overlap for these respective results strongly suggests that there was no difference between them. Fifth, we did not have access to data regarding the likely aetiology of HF though, based on the characteristics of the trial participants, relatively few are likely to have developed preserved ejection HF. Sixth, we were unable to compare outcomes in men and women.

In conclusion, our meta-analysis of data from major trials demonstrated that statin therapy modestly reduced the risk of non-fatal HF hospitalization and the composite outcome of HF death and non-fatal hospitalization over 4.3 years.

Authors’ contributions

D.P. had access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: D.P., R.T.C., J.J.M. Acquisition of data: all authors. Analysis and interpretation of data: all authors. Drafting of the manuscript: D.P., R.T.C., J.J.M. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: D.P. Administrative, technical, or material support: none. Study supervision: J.J.M.

Role of the sponsor

The British Heart Foundation had no role in the design and conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.

Supplementary material

Supplementary material is available at European Heart Journal online.

Acknowledgements

We acknowledge the considerable support of Drs DeMicco and Breazna (both employees of Pfizer) and Pfizer who supplied unpublished data for the following trials: Collaborative Atorvastatin Diabetes Study, Aggressive Lipid-Lowering Initiation Abates New Cardiac Events study, Treating to New Targets Study, Incremental Decrease in Events Through Aggressive Lipid-Lowering Study, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus, Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. We are grateful to the investigators from the following trials for providing unpublished data: West of Scotland Coronary Prevention Study, Cholesterol and Recurrent Events trial, Air Force/Texas Coronary Atherosclerosis Prevention Study, Gruppo Italiano per lo Studio della Sopravvenienza nell’Insufficienza cardiaca Prevenzione, Heart Protection Study, Prospective Study of Pravastatin in the Elderly at Risk, Greek Atorvastatin and Coronary Heart Disease Evaluation Study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine.

Funding

This project was not supported by external funding. R.T.C. is funded by a BHF project grant (PG/13/17/30050). N.R.P. is supported by the National Institute for Health Research Senior Investigator Awards, Biomedical Research Centre funding, and the British Heart Foundation Research Centre Excellence Award. K.R. is supported by a National Institute for Health Research Career Development Fellowship and funding from the Oxford Biomedical Research Centre, and the Oxford Martin School. Funding to pay the Open Access publication charges for this article was provided by the University of Glasgow.

Conflict of interest: I.F., C.J.P., K.R., H.M.C., D.D.W., J.C.L., P.A., T.R.P., M.J.T., M.J.K., N.R.P., P.S.S., P.M.R., J.G.M., B.R.D., H.N., K.M., R.M.M., R.M., G.T., V.G.A., A.M.G., M.B.C., and J.R.D. each reported serving as an investigator in at least one of the trials. D.P. reports serving on advisory boards for Sanofi Aventis. I.F. reports receiving a research grant from Merck. C.J.P. reports receiving a research grant funding from AstraZeneca, MSD, and Roche, plus consulting for AstraZeneca, MSD, and Roche. N.S. has received consulting fees as a member of the Advisory Boards of AstraZeneca, Bristol Meyers Squibb, Amgen, and Sanofi, and received an honorarium as a speaker for MSD. H.M.C. has been a consultant or advisory panel member for Pfizer, Sanofi Aventis, Regeneron, Novartis, and Eli Lilly, has received non-binding research support from Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, and AstraZeneca, has participated in a lecture/speaker’s bureau and received honoraria from Pfizer, and is a shareholder in Roche. D.D.W. reports receiving remuneration for participating in clinical trial committees for Astra, Aegerion, Cerenis, CSL Ltd, Merck Schering-Plough, Pfizer, Shire, and Sanofi-Aventis; consulting for Anthera, Genentech, Pfizer, Roche, and Servier; and receiving speaker’s honoraria from Bristol Myers Squibb, Pfizer, and Zydus Medica. J.C.L. reports consulting for Pfizer and serving on advisory groups for Amgen. P.A. reports receipt of research grant support and lecture fees from Pfizer, Sanofi, Bristol-Myers Squibb, Merck, AstraZeneca, and Boehringer-Ingelheim, plus consulting fees from Pfizer, BMS, Merck, Boehringer-Ingelheim, AstraZeneca, Bayer, Daiichi-Sankyo, Lundbeck, Edwards, Boston Scientific, Kowa, and lecture fees from Bayer, Boston Scientific, St Jude Medical. T.R.P. reports receiving speakers’ honoraria from Merck (MSD), Pfizer, AstraZeneca, Roche, and Amgen; consulting for Merck (MSD) and Amgen; and receiving research grants from Merck (MSD) and Amgen. M.J.T. reports serving on advisory boards for Amgen and Aegerion; receiving a steering committee honorarium from Pfizer; receiving research grant funding and travel grants from Amgen and Pfizer. M.J.K. is an employee of a company that has received research grants for the evaluation of lipid treatments from Amgen, Eli Lilly, Pfizer, Regeneron, Roche, and Sanofi-Aventis. N.R.P. reports receiving speaker’s honoraria from Pfizer and Kowa. P.S.S has served as a consultant to, received travel expenses from, and received payment for speaking at meetings for and received research funding from Pfizer, P.M.R. has received investigator initiated research grants from AstraZeneca, Novartis, Pfizer, and Amgen; serving as a consultant to Merck, ISIS, and Boston Heart; and is listed as a coinventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. S.D.S. reports receiving consulting fees and grant

1544

D. Preiss et al.
support from Novartis and consulting fees from Bayer. K.M. reports receiving lecture fees from Daichi Sankyo, Merk-Banyu, Pfizer, Kowa, Astellas, Astra Zeneca, Novartis, Mitsubishi, and Tanabe. A.M.G. is on the Board of Directors of Agerion Pharmaceuticals, Arisaph Pharmaceuticals, and Esperion Therapeutics, has been on advisory boards for Vatera Capital and Dupont, and has consulted for AstraZeneca, Janssen, Kowa, Merck, Pfizer, and Roche. M.B.C. is a consultant to, receives honoraria from, and had travel/accommodations expenses covered or reimbursed by Astra Zeneca and Daichi Sankyo. K.K.R. reports receiving honoraria for lectures or advisory boards for Pfizer, AstraZeneca, Roche, Sanofi, Regeneron, Amgen, Kowa, Aegerion, Abbott, Takeda, Novo Nordisk, and Boehringer Ingelheim, plus research grants from Pfizer, Bristol Myers Squibb, Sanofi Solvay, and Regeneron/Sanoﬁ.

References


